Recent Posts
- Sermonix Pharmaceuticals to Collaborate With Eli Lilly and Company in Studying Combination of Lasofoxifene and Lilly’s CDK 4 and 6 Inhibitor, Abemaciclib, in Metastatic Breast Cancer
- Sermonix to Present Poster on Lasofoxifene, CDK 4/6 Inhibitor Combination for AACR Virtual Annual Meeting
- Sermonix to Co-sponsor ‘Candid Conversations’ Patient Advocacy Panel With Breastcancer.org at San Antonio Breast Cancer Symposium
- Sermonix Doses First Patient in Phase 2 Clinical Trial of Lasofoxifene for Targeted Precision Medicine Treatment of Women With ESR1 Mutations in Metastatic Breast Cancer
- Sermonix to Present Poster on Oncologists’ Perception of Sexual Intimacy Issues in Treatment of Metastatic Breast Cancer at 2019 North American Menopause Society Annual Meeting
Recent Comments